16% Increase in China Resources Sanju Mdcl & Phrm (000999) Earnings: FY Net Income Hits 2.85B Yuan

China Resources Sanju Mdcl & Phrm on Smartkarma

China Resources Sanju Mdcl & Phrm, a leading pharmaceutical company in China, has recently been covered by independent analysts on Smartkarma, an investment research network. In a report by Xinyao (Criss) Wang, it was analyzed that the true value of licensing deals can be determined by the direct and non-refundable upfront payment, rather than the total or subsequent milestone payments. The report also delved into the stable pricing levels of innovative drugs in China’s National Reimbursement Drug List (NRDL), with three levels identified. Additionally, the report provided insights on the impact of anti-corruption measures and weak performance in the TCM formula granules business on China Resources Sanju in the third quarter of 2023, which could potentially affect its performance in the second half of the year.

A look at China Resources Sanju Mdcl & Phrm Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has a promising long-term outlook, according to the Smartkarma Smart Scores. The company received a score of 3 for value, indicating that it is priced fairly in the market. Additionally, it scored a 4 for both dividend and growth potential, indicating that it is a stable company with potential for future growth. Furthermore, China Resources Sanju Mdcl & Phrm scored a 4 for resilience, meaning it has a strong ability to withstand economic downturns. Finally, the company received a perfect score of 5 for momentum, suggesting that it is currently performing well in the market. These scores paint a positive picture for the future of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

Based on the Smartkarma Smart Scores, China Resources Sanju Mdcl & Phrm is a diverse company with a strong presence in the medical and pharmaceutical industry. In addition to manufacturing and marketing medicines, healthcare products, and medical instruments, the company also operates in pharmaceutical trading, printing, food manufacturing, real estate development, and provides medical services. With a solid score of 4 for resilience and a perfect score of 5 for momentum, China Resources Sanju Mdcl & Phrm is well-positioned for continued success and growth in the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma